Newsroom All the latest news from the Pierre Fabre Group Page inner navigation PRESS RELEASES PRESS AREA NEWS PUBLICATIONS TWITTER Press releases Filter Year Year2026202520242023202220212020 Month MonthJanuaryFebruaryMarchAprilMayJuneJulyAugustSeptemberOctoberNovemberDecember Écrit le Min Max Appliquer Press release Aglaia Therapeutics becomes Ribonexus and signs exclusive license agreement with Pierre Fabre on small molecules targeting eIF4A, an innovative target in oncology 18 November 2021 Press release Pierre Fabre and the EspeRare Foundation start the EDELIFE clinical trial of a prenatal treatment for a rare genetic disease, XLHED 15 November 2021 Press release Talem Therapeutics Announces Multi-Target Antibody Discovery Research Collaboration with Pierre Fabre 7 October 2021 Load more Presse area Are you a journalist? Find all the press releases of the Pierre Fabre group. Join us News Filter Year Year2026202520242023202220212020 Month MonthJanuaryFebruaryMarchAprilMayJuneJulyAugustSeptemberOctoberNovemberDecember Tags (field_news_tags) - Any -#CRCawarenessAcneCastres OlympiqueCompanySeborrheic dermatitisDermo-cosmétiqueDuoDayE-SANTÉEngagementHappy New YearKnow Your LemonsLittle Big DreamsPharmaPierre Fabre expertiseInternational Men's Day#OurBreastJourneyCOLLECTION PIERRE FABREConsortiumSustainable developmentDIGITALEADVESMOThe Gustave Roussy PrizeLettre OuverteLymphomaMedicalInnovationMedicalScienceLiaisonMelanomaMSLPink OctoberOncologyANNUAL REPORTStudyEventsPierre Fabre FoundationInnovationNominationsPartnershipsAwardsStrategyTalents Écrit le Min Max Appliquer Events Metastatic Colorectal Cancer World Day 21 September 2022 Events CHANGING THE WAY WE LOOK AT VISIBLE DERMATOSES 26 July 2022 Events PIERRE FABRE, 60 YEARS OF CARING FOR EVERYONE 18 July 2022 Strategy The Pierre Fabre Group unveils its Purpose 17 February 2020 Load more Publications Aucun résultat
Press release Aglaia Therapeutics becomes Ribonexus and signs exclusive license agreement with Pierre Fabre on small molecules targeting eIF4A, an innovative target in oncology 18 November 2021
Press release Pierre Fabre and the EspeRare Foundation start the EDELIFE clinical trial of a prenatal treatment for a rare genetic disease, XLHED 15 November 2021
Press release Talem Therapeutics Announces Multi-Target Antibody Discovery Research Collaboration with Pierre Fabre 7 October 2021
